|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||84.28 - 86.29|
|52-week range||74.92 - 91.14|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.35|
|Earnings date||04 Feb 2022|
|Forward dividend & yield||3.20 (3.69%)|
|Ex-dividend date||05 May 2021|
|1y target est||102.56|
Chinese tech giant Baidu Inc said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker. Sanofi had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech/Pfizer and Moderna in developing mRNA shots against COVID-19. Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Actually, investors can have their cake and eat it too, balancing current income with principal appreciation.